Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29962871 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31031947 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31164312 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL15160677 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31164313 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL16379393 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31164311 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL15155687 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL15160681 | 1.00 | KMT2A (0.75) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Ammonia Solution, Strong SCHEMBL4536970 | 0.99 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045567-B | Phosphatase recruitment chimera (PHORCs) compound based on protein phosphatase 5, preparation method and medical application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-113045567-A | Phosphatase recruitment chimera (PHORCs) compound based on protein phosphatase 5, preparation method and medical application thereof | 中国药科大学 | 2021-06-29 | — | — | CN | disclosed |
| CN-108770357-A | Polymer combined vaccine | 芝加哥大学 | 2018-11-06 | — | — | CN | disclosed |
| US-10023861-B2 | Oligomer-conjugate complexes and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9790253-B2 | OSW-1 analogs and conjugates, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2809660-B1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORP (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-20140135279-A1 | OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2710024-A2 | OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF | President and Fellows of Harvard College (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2012159027-A2 | OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120196989-A1 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | INTEZYNE TECHNOLOGIES, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20060246438-A1 | Methods for the chemical and physical modification of nanotubes, methods for linking the nanotubes, methods for the directed positioning of nanotubes, and uses thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | KMT2A 3399/4885EPHX2 1747/4885TLR2 456/4885 |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | PARG, PCNA, PARN | KMT2A 3554/4885EPHX2 428/4885TLR2 1443/4885 |
| US-20140135279-A1 | OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF | OSBP, OSBP2, OSBPL3 | KMT2A 3951/4885EPHX2 1934/4885TLR2 3511/4885 |
| US-10023861-B2 | Oligomer-conjugate complexes and their use | DCLRE1B, NT5C3B, PAICS | KMT2A 1842/4885EPHX2 1284/4885TLR2 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.